Border to Coast Pensions Partnership Ltd Decreases Stock Position in West Pharmaceutical Services, Inc. $WST

Posted by George Bondi on Jun 28th, 2026

Border to Coast Pensions Partnership Ltd decreased its position in West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 4.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 226,857 shares of the medical instruments supplier’s stock after selling 9,450 shares during the quarter. Border to Coast Pensions Partnership Ltd’s holdings in West Pharmaceutical Services were worth $57,034,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. Norges Bank acquired a new position in shares of West Pharmaceutical Services during the fourth quarter worth $272,041,000. Generation Investment Management LLP grew its holdings in West Pharmaceutical Services by 60.0% during the 4th quarter. Generation Investment Management LLP now owns 1,561,869 shares of the medical instruments supplier’s stock valued at $429,733,000 after purchasing an additional 585,855 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in West Pharmaceutical Services by 67.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,174,962 shares of the medical instruments supplier’s stock valued at $323,280,000 after purchasing an additional 473,547 shares in the last quarter. Steadfast Capital Management LP purchased a new stake in West Pharmaceutical Services during the 3rd quarter worth $123,667,000. Finally, AQR Capital Management LLC increased its stake in West Pharmaceutical Services by 420.1% during the 3rd quarter. AQR Capital Management LLC now owns 545,879 shares of the medical instruments supplier’s stock worth $142,949,000 after buying an additional 440,929 shares during the period. Hedge funds and other institutional investors own 93.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on WST shares. Barclays raised shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $310.00 to $400.00 in a research report on Tuesday, June 9th. Evercore reaffirmed an “outperform” rating on shares of West Pharmaceutical Services in a research report on Friday, April 24th. Citigroup reiterated a “buy” rating on shares of West Pharmaceutical Services in a research note on Friday, April 24th. Wolfe Research began coverage on West Pharmaceutical Services in a report on Monday, June 1st. They issued an “outperform” rating and a $375.00 price target for the company. Finally, Stephens restated an “overweight” rating and set a $360.00 price objective on shares of West Pharmaceutical Services in a research note on Tuesday, June 2nd. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $340.09.

View Our Latest Research Report on WST

West Pharmaceutical Services Price Performance

WST opened at $351.07 on Friday. The company has a market capitalization of $24.80 billion, a P/E ratio of 46.93, a PEG ratio of 2.94 and a beta of 1.18. The company has a 50-day moving average of $313.84 and a 200-day moving average of $275.59. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.04 and a current ratio of 2.71. West Pharmaceutical Services, Inc. has a 1-year low of $206.80 and a 1-year high of $352.31.

West Pharmaceutical Services (NYSE:WST – Get Free Report) last issued its quarterly earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 EPS for the quarter, topping the consensus estimate of $1.68 by $0.45. The business had revenue of $844.90 million for the quarter, compared to analysts’ expectations of $779.67 million. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The company’s quarterly revenue was up 21.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.45 earnings per share. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. Equities analysts expect that West Pharmaceutical Services, Inc. will post 8.6 EPS for the current fiscal year.

Insider Buying and Selling

In other news, VP Annette F. Favorite sold 2,817 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the sale, the vice president directly owned 16,828 shares in the company, valued at approximately $5,135,905.60. The trade was a 14.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Chad Winters sold 896 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $300.67, for a total value of $269,400.32. Following the sale, the chief accounting officer directly owned 1,523 shares in the company, valued at approximately $457,920.41. This represents a 37.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 0.60% of the company’s stock.

About West Pharmaceutical Services

(Free Report)

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.